Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $15.63, for a total value of $156,300.00. Following the completion of the transaction, the chief financial officer now directly owns 117,622 shares in the company, valued at $1,838,431.86. The transaction was disclosed in a filing with the SEC, which is available at this link.
Amicus Therapeutics traded down $0.05, hitting $15.90, during midday trading on Thursday, MarketBeat reports. The company’s stock had a trading volume of 1,521,800 shares, compared to its average volume of 2,783,068. The stock has a market capitalization of $3.01 billion, a PE ratio of -5.43 and a beta of 1.38. Amicus Therapeutics, Inc. has a 12 month low of $10.09 and a 12 month high of $17.62. The company has a current ratio of 4.21, a quick ratio of 4.15 and a debt-to-equity ratio of 0.32.
Get Amicus Therapeutics alerts:Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. The business had revenue of $16.70 million during the quarter, compared to analyst estimates of $16.78 million. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. research analysts predict that Amicus Therapeutics, Inc. will post -1.3 earnings per share for the current year.
Several equities analysts recently issued reports on the company. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 13th. ValuEngine raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 20th. Finally, Cowen reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research report on Tuesday, May 8th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $19.06.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA raised its stake in Amicus Therapeutics by 14.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 39,810 shares of the biopharmaceutical company’s stock valued at $599,000 after buying an additional 4,923 shares during the last quarter. Teachers Advisors LLC raised its stake in Amicus Therapeutics by 0.9% during the 4th quarter. Teachers Advisors LLC now owns 663,936 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 5,858 shares during the last quarter. American International Group Inc. raised its stake in Amicus Therapeutics by 5.9% during the 1st quarter. American International Group Inc. now owns 119,167 shares of the biopharmaceutical company’s stock valued at $1,792,000 after buying an additional 6,684 shares during the last quarter. QS Investors LLC raised its stake in Amicus Therapeutics by 4.9% during the 4th quarter. QS Investors LLC now owns 159,008 shares of the biopharmaceutical company’s stock valued at $2,288,000 after buying an additional 7,483 shares during the last quarter. Finally, MetLife Investment Advisors LLC raised its stake in Amicus Therapeutics by 11.3% during the 1st quarter. MetLife Investment Advisors LLC now owns 85,724 shares of the biopharmaceutical company’s stock valued at $1,289,000 after buying an additional 8,736 shares during the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
No comments:
Post a Comment